347 related articles for article (PubMed ID: 34083232)
1. First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Maitland ML; Sachdev JC; Sharma MR; Moreno V; Boni V; Kummar S; Stringer-Reasor E; Lakhani N; Moreau AR; Xuan D; Li R; Powell EL; Jackson-Fisher A; Bowers M; Alekar S; Xin X; Tolcher AW; Calvo E
Clin Cancer Res; 2021 Aug; 27(16):4511-4520. PubMed ID: 34083232
[TBL] [Abstract][Full Text] [Related]
2. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
Gerber DE; Infante JR; Gordon MS; Goldberg SB; Martín M; Felip E; Martinez Garcia M; Schiller JH; Spigel DR; Cordova J; Westcott V; Wang Y; Shames DS; Choi Y; Kahn R; Dere RC; Samineni D; Xu J; Lin K; Wood K; Royer-Joo S; Lemahieu V; Schuth E; Vaze A; Maslyar D; Humke EW; Burris HA
Clin Cancer Res; 2020 Jan; 26(2):364-372. PubMed ID: 31540980
[TBL] [Abstract][Full Text] [Related]
3. Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.
Radovich M; Solzak JP; Wang CJ; Hancock BA; Badve S; Althouse SK; Bray SM; Storniolo AMV; Ballinger TJ; Schneider BP; Miller KD
Clin Cancer Res; 2022 Aug; 28(15):3235-3241. PubMed ID: 35551360
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
[TBL] [Abstract][Full Text] [Related]
5. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.
King GT; Eaton KD; Beagle BR; Zopf CJ; Wong GY; Krupka HI; Hua SY; Messersmith WA; El-Khoueiry AB
Invest New Drugs; 2018 Oct; 36(5):836-847. PubMed ID: 29333575
[TBL] [Abstract][Full Text] [Related]
6. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
Garrido-Laguna I; Krop I; Burris HA; Hamilton E; Braiteh F; Weise AM; Abu-Khalaf M; Werner TL; Pirie-Shepherd S; Zopf CJ; Lakshminarayanan M; Holland JS; Baffa R; Hong DS
Int J Cancer; 2019 Oct; 145(7):1798-1808. PubMed ID: 30680712
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Camidge DR; Morgensztern D; Heist RS; Barve M; Vokes E; Goldman JW; Hong DS; Bauer TM; Strickler JH; Angevin E; Motwani M; Parikh A; Sun Z; Bach BA; Wu J; Komarnitsky PB; Kelly K
Clin Cancer Res; 2021 Nov; 27(21):5781-5792. PubMed ID: 34426443
[TBL] [Abstract][Full Text] [Related]
8. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
Weekes CD; Lamberts LE; Borad MJ; Voortman J; McWilliams RR; Diamond JR; de Vries EG; Verheul HM; Lieu CH; Kim GP; Wang Y; Scales SJ; Samineni D; Brunstein F; Choi Y; Maslyar DJ; Colon-Otero G
Mol Cancer Ther; 2016 Mar; 15(3):439-47. PubMed ID: 26823490
[TBL] [Abstract][Full Text] [Related]
10. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.
Rosen LS; Wesolowski R; Baffa R; Liao KH; Hua SY; Gibson BL; Pirie-Shepherd S; Tolcher AW
Invest New Drugs; 2020 Feb; 38(1):120-130. PubMed ID: 30887250
[TBL] [Abstract][Full Text] [Related]
11. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
[TBL] [Abstract][Full Text] [Related]
12. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
Damelin M; Bankovich A; Bernstein J; Lucas J; Chen L; Williams S; Park A; Aguilar J; Ernstoff E; Charati M; Dushin R; Aujay M; Lee C; Ramoth H; Milton M; Hampl J; Lazetic S; Pulito V; Rosfjord E; Sun Y; King L; Barletta F; Betts A; Guffroy M; Falahatpisheh H; O'Donnell CJ; Stull R; Pysz M; Escarpe P; Liu D; Foord O; Gerber HP; Sapra P; Dylla SJ
Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077676
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors.
Tolaney SM; Do KT; Eder JP; LoRusso PM; Weekes CD; Chandarlapaty S; Chang CW; Chen SC; Nazzal D; Schuth E; Brunstein F; Carrasco-Triguero M; Darbonne WC; Giltnane JM; Flanagan WM; Commerford SR; Ungewickell A; Shapiro GI; Modi S
Clin Cancer Res; 2020 Nov; 26(21):5588-5597. PubMed ID: 32694157
[TBL] [Abstract][Full Text] [Related]
14. MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors.
Kong C; Pu J; Zhao Q; Weng W; Ma L; Qian Y; Hu W; Meng X; Meng T
Mol Cancer Ther; 2023 Oct; 22(10):1128-1143. PubMed ID: 37352387
[TBL] [Abstract][Full Text] [Related]
15. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Liu J; Burris H; Wang JS; Barroilhet L; Gutierrez M; Wang Y; Vaze A; Commerford R; Royer-Joo S; Choeurng V; Humke E; Moore K
Gynecol Oncol; 2021 Dec; 163(3):473-480. PubMed ID: 34627611
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
[TBL] [Abstract][Full Text] [Related]
17. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
Hamilton E; O'Malley DM; O'Cearbhaill R; Cristea M; Fleming GF; Tariq B; Fong A; French D; Rossi M; Brickman D; Moore K
Gynecol Oncol; 2020 Sep; 158(3):640-645. PubMed ID: 32513564
[TBL] [Abstract][Full Text] [Related]
18. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Moore KN; Birrer MJ; Marsters J; Wang Y; Choi Y; Royer-Joo S; Lemahieu V; Armstrong K; Cordova J; Samineni D; Schuth E; Vaze A; Maslyar D; Humke EW; Hamilton EP; Liu JF
Gynecol Oncol; 2020 Sep; 158(3):631-639. PubMed ID: 32534811
[TBL] [Abstract][Full Text] [Related]
19. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Santin AD; Vergote I; González-Martín A; Moore K; Oaknin A; Romero I; Diab S; Copeland LJ; Monk BJ; Coleman RL; Herzog TJ; Siegel J; Kasten L; Schlicker A; Schulz A; Köchert K; Walter AO; Childs BH; Elbi C; Bulat I
Int J Gynecol Cancer; 2023 Apr; 33(4):562-570. PubMed ID: 36564099
[TBL] [Abstract][Full Text] [Related]
20. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
Shimizu T; Sands J; Yoh K; Spira A; Garon EB; Kitazono S; Johnson ML; Meric-Bernstam F; Tolcher AW; Yamamoto N; Greenberg J; Kawasaki Y; Zebger-Gong H; Kobayashi F; Phillips P; Lisberg AE; Heist RS
J Clin Oncol; 2023 Oct; 41(29):4678-4687. PubMed ID: 37327461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]